Vandria’s VNA-318 enters clinical trials for treating age-related diseases
Vandria - 18-Dec-2024Early tests have shown VNA-318 could improve brain function and reduce brain cell damage
Join the club for FREE to access the whole archive and other member benefits.
Developing mitophagy inducers to treat age-related and chronic diseases
Vandria discovers and develops inhibitors of a novel target which results in the induction of mitophagy - the selective removal and replacement of damaged mitochondria - and anti-inflammatory effects. The target has strong genetic links to several human diseases.
In pre-clinical studies, Vandria’s lead candidate, VNA-318, has been consistently shown to acutely improve memory and learning, and to have strong disease-modifying effects in models of neurodegenerative disease such as Alzheimer’s and Parkinson’s Disease. Toxicity studies have demonstrated VNA-318 to have a wide safety window.
Visit website: https://www.vandria.com/
Details last updated 15-Dec-2023
Early tests have shown VNA-318 could improve brain function and reduce brain cell damage
New funding propels innovative mitophagy-inducing lead compound into clinical trials targeting Alzheimer’s and Parkinson’s
Mitophagy-boosting drug candidate VNA-318 preps for clinical trials